Biotech · Public company · Carmel, IN, US
MBX Biosciences, Inc.
Ticker MBX · SEC CIK 0001776111
Track this companyFree. Adds MBX Biosciences, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials83 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline12
- CanvuparatidePhase 3 · HypoparathyroidismClinicalTrials.gov · fetched Nov 12, 2026
- 200-1600 µg of MBX 2109 once-weekly by subcutaneous injectionPhase 2 · HypoparathyroidismClinicalTrials.gov · fetched Nov 12, 2026
- 400 µg of MBX 2109 once-weekly by subcutaneous injectionPhase 2 · HypoparathyroidismClinicalTrials.gov · fetched Nov 12, 2026
- MBX 1416 (INN imapextide)Phase 2 · Postbariatric HypoglycemiaClinicalTrials.gov · fetched Nov 12, 2026
- MBX 2109Phase 2 · HypoparathyroidismClinicalTrials.gov · fetched Nov 12, 2026
- MBX 1416 (Part A)Phase 1 · Postbariatric HypoglycemiaClinicalTrials.gov · fetched Nov 12, 2026
- MBX 1416 (Part B)Phase 1 · Postbariatric HypoglycemiaClinicalTrials.gov · fetched Nov 12, 2026
- MBX 1416 (Part C)Phase 1 · Postbariatric HypoglycemiaClinicalTrials.gov · fetched Nov 12, 2026
- MBX 2109Phase 1 · Renal ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- MBX 2109 (Part A)Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- MBX 2109 (Part B)Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- MBX 4291Phase 1 · ObesityClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With HypoparathyroidismPHASE3 · RECRUITING · started Aug 26, 2026ClinicalTrials.gov NCT07699471 · fetched Nov 12, 2026
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With ObesityPHASE1 · RECRUITING · started Sep 3, 2025ClinicalTrials.gov NCT07142707 · fetched Nov 12, 2026
- Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)PHASE2 · COMPLETED · started Aug 26, 2025ClinicalTrials.gov NCT07029412 · fetched Nov 12, 2026
- Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With HypoparathyroidismPHASE2 · ACTIVE_NOT_RECRUITING · started Oct 31, 2024ClinicalTrials.gov NCT06531941 · fetched Nov 12, 2026
- Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With HypoparathyroidismPHASE2 · COMPLETED · started Aug 8, 2024ClinicalTrials.gov NCT06465108 · fetched Nov 12, 2026
- Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal FunctionPHASE1 · COMPLETED · started Jun 13, 2024ClinicalTrials.gov NCT06496217 · fetched Nov 12, 2026
- Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy SubjectsPHASE1 · COMPLETED · started Sep 18, 2023ClinicalTrials.gov NCT06036784 · fetched Nov 12, 2026
- Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult SubjectsPHASE1 · COMPLETED · started Nov 10, 2021ClinicalTrials.gov NCT05158335 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 22, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 27, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 11, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026